Products Research Area/Disease Cancer CircuLex S100P ELISA Kit
CircuLex S100P ELISA Kit
CircuLex S100P ELISA Kit.

Specifications:
Description
The CircuLex S100P ELISA Kit is used for the quantitative measurement of S100P in cell lysate, cell culture conditioned medium, serum, plasma and other biological media. It can be used for 96 Assays.
Target: | S100P |
---|---|
Product Type: | ELISA Kit |
Size: | 96 Assays |
Application: | ELISA |
Research Area / Disease: | Immunology, Neuroscience |
Sensitivity: | better than 0.2 ng/ml of sample. |
Measurement Range: | Results exceeding S100P level of 5 ng/ml should be repeated with diluted samples. Dilution factors needto be taken into consideration in calculating the S100P concentration. |
Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
Components
- Microplate
- 10X Wash Buffer
- Dilution Buffer
- Human S100P Standard
- HRP conjugated Detection Antibody
- Substrate Reagent
- Stop Solution
Citations
- Mori Y et al. A minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma using biomarkers in duodenal juice. Pancreas. 42, 187-92 (2013),
- Saito T et al. Distinct expression patterns of alveolar “alarmins” in subtypes of chronic lung allograft dysfunction. Am J Transplant. 14, 1425-32 (2014),
- Sato Y et al. Clinicopathological significance of S100 protein expression in cholangiocarcinoma. J Gastroenterol Hepatol. 28, 1422-9 (2013)
References
- Becker, T., Gerke, V., Kube, E., and Weber, K. (1992) Eur. J. Biochem. 207, 541–547
- Emoto, Y., Kobayashi, R., Akatsuka, H., and Hidaka, H. (1992) Biochem. Biophys. Res. Commun. 182, 1246–1253
- Zhang, H., Wang, G., Ding, Y., Wang, Z., Barraclough, R., Rudland, P. S., Fernig, D. G., and Rao, Z. (2003) J. Mol. Biol. 325, 785–794
- Sato, N., and Hitomi, J. (2002) Anat. Rec. 267, 60–69
- Guerreiro, D. S., I, Hu, Y. F., Russo, I. H., Ao, X., Salicioni, A. M., Yang, X., and Russo, J. (2000) Int. J. Oncol. 16, 231–240
- Bertram, J., Palfner, K., Hiddemann, W., and Kneba, M. (1998) Anticancer Drugs 9, 311–317
- Averboukh, L., Liang, P., Kantoff, P. W., and Pardee, A. B. (1996) Prostate 29, 350–355
- Logsdon, C. D., Simeone, D. M., Binkley, C., Arumugam, T., Greenson, J. K., Giordano, T. J., Misek, D. E., and Hanash, S. (2003) Cancer Res. 63, 2649–2657
- Beer, D. G., Kardia, S. L., Huang, C. C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., Lizyness, M. L., Kuick, R., Hayasaka, S., Taylor, J. M., Iannettoni, M. D., Orringer, M. B., and Hanash, S. (2002) Nat. Med. 8, 816–824
Related Content:
Pathway Posters
Rho Family Pathway